Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Butenafine Hydrochloride 1%
Generic Name
Butenafine Hydrochloride
Active Ingredient
ButenafineCategory
Other
Salt Form
Hydrochloride
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 10 mg/g | CREAM | TOPICAL | 69842-989 |
Detailed information about Butenafine Hydrochloride 1%
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Butenafine Hydrochloride 1%, you must consult a qualified healthcare professional.
Butenafine is a potent benzylamine antifungal agent used topically to treat various skin infections, including athlete's foot and ringworm. It works by inhibiting ergosterol synthesis, essential for fungal cell membrane integrity.
The dosage and duration of butenafine treatment depend specifically on the type of fungal infection being treated. It is vital to complete the full course of treatment even if symptoms improve quickly to prevent the infection from returning.
Butenafine is generally approved for use in children aged 12 years and older. The dosage for adolescents is the same as the adult dosage for each respective condition. The safety and efficacy of butenafine in children under the age of 12 have not been established. If a child under 12 has a skin rash, a pediatrician should be consulted for a proper diagnosis and treatment plan.
Because butenafine is applied topically and systemic absorption is negligible (less than 1.5%), dosage adjustments are generally not required for patients with kidney disease. However, patients with end-stage renal disease should always inform their doctor of all topical medications.
Similarly, while the absorbed portion of butenafine is metabolized by the liver, the systemic levels are so low that hepatic impairment does not typically necessitate a change in the topical dosing schedule.
Clinical trials have not identified significant differences in safety or efficacy between elderly patients and younger adults. No specific dosage adjustments are recommended for the geriatric population, though care should be taken to ensure the skin is intact and not severely compromised.
Proper application technique is essential for the success of antifungal therapy:
If you miss a dose, apply it as soon as you remember. If it is almost time for your next scheduled application, skip the missed dose and return to your regular schedule. Do not apply extra cream to "make up" for a missed dose, as this will not speed up the healing process and may increase the risk of skin irritation.
Because butenafine is for external use only, a systemic overdose from topical application is highly unlikely. However, if the medication is accidentally swallowed, contact a Poison Control Center or seek emergency medical attention immediately. Symptoms of ingestion might include gastrointestinal upset or nausea. If the cream gets into the eyes, rinse them thoroughly with cool water for several minutes.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop treatment early without medical guidance, as incomplete treatment is the most common cause of fungal recurrence.
Butenafine is generally very well-tolerated because it acts locally on the skin. However, some patients may experience mild application site reactions. These are typically transient and do not require discontinuation of the medication. Common reactions include:
In some individuals, the skin may be more sensitive to the active ingredient or the inactive components of the cream (such as preservatives or emulsifiers). These effects may include:
Rarely, more significant skin reactions can occur. These may include:
While systemic absorption is minimal, severe allergic reactions can occur. You should stop using Butenafine and contact a healthcare professional immediately if you experience:
> Warning: Stop taking Butenafine and call your doctor immediately if you experience any signs of a severe allergic reaction or if your skin condition worsens significantly after starting the medication.
Butenafine is intended for short-term use (typically 1 to 4 weeks). There are no documented long-term systemic side effects associated with the proper topical use of butenafine. However, prolonged use beyond the recommended timeframe or use on large areas of broken skin could theoretically increase the risk of skin thinning or localized sensitization. If an infection does not clear within the recommended treatment window, a healthcare provider should re-evaluate the diagnosis rather than continuing the medication indefinitely.
There are currently no FDA black box warnings for butenafine hydrochloride. It is considered a safe and effective topical treatment when used as directed for its approved indications.
Report any unusual symptoms or persistent skin irritation to your healthcare provider to ensure the best possible outcome for your treatment.
Butenafine is for external use only. It must not be used in the eyes, mouth, or vagina. If the medication comes into contact with the eyes, it can cause severe irritation; if this occurs, rinse the eyes thoroughly with water for at least 15 minutes. Additionally, butenafine should not be applied to highly inflamed or broken skin unless directed by a physician, as this could increase the small amount of systemic absorption.
No FDA black box warnings for Butenafine. This medication has a well-established safety profile for topical administration in both prescription and over-the-counter settings.
For standard topical use, no routine laboratory monitoring (such as blood counts or liver function tests) is required. This is a significant advantage over oral antifungal medications like terbinafine or itraconazole, which often require baseline and periodic liver enzyme monitoring. However, if the infection does not show signs of improvement after the full course of treatment, your healthcare provider may perform a fungal culture or skin biopsy to confirm the diagnosis.
Butenafine does not cause drowsiness, dizziness, or visual disturbances. It has no known effect on the ability to drive or operate heavy machinery.
There are no known interactions between topical butenafine and alcohol consumption. Unlike some oral antifungals that can interact with alcohol to cause liver stress or disulfiram-like reactions, topical butenafine is safe to use regardless of alcohol intake.
There is no risk of a withdrawal syndrome when stopping butenafine. However, premature discontinuation is the leading cause of treatment failure. You must continue the application for the full duration prescribed by your doctor, even if the skin looks normal. Fungal spores can remain in the skin even after the visible rash has cleared, and stopping early allows these spores to regrow, leading to a recurrence of the infection.
> Important: Discuss all your medical conditions, especially any history of skin sensitivity or allergies, with your healthcare provider before starting Butenafine.
There are no documented drug-drug interactions that are considered absolutely contraindicated with the topical use of butenafine. Because the systemic levels of the drug are negligible, it does not interfere with the metabolism of internal medications. However, it should not be used simultaneously on the same area of skin with other topical medications unless specifically directed by a healthcare provider, as this could alter the absorption or efficacy of both products.
While butenafine does not interact with systemic drugs, caution is advised when using other topical agents that may compromise the skin barrier. For example, using harsh chemical exfoliants or topical corticosteroids on the same area may increase the irritation potential of butenafine. If you are using a topical steroid for inflammation, your doctor may recommend applying it at a different time of day than the antifungal cream.
There are no known moderate interactions with systemic medications. Theoretically, if butenafine were absorbed in large quantities, it might interact with drugs metabolized by the CYP450 system, but clinical studies have shown that even with maximal use, plasma levels are too low to cause such interactions.
There are no known interactions between topical butenafine and food. Unlike oral antifungals, which may require a high-fat meal for absorption (like griseofulvin) or be affected by grapefruit juice, butenafine's efficacy is entirely independent of diet. You do not need to change your eating habits while using this medication.
There are no documented interactions between topical butenafine and herbal supplements such as St. John’s Wort, ginkgo biloba, or valerian root. Because the drug does not reach significant levels in the bloodstream, it does not compete with these supplements for metabolic enzymes.
Butenafine is not known to interfere with common laboratory tests, including blood chemistry, hematology, or urinalysis. It does not affect the results of glucose tests, liver function panels, or kidney function tests.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, even if they are "just for the skin," to ensure there are no unintended interactions.
Butenafine must NEVER be used in the following circumstances:
Relative contraindications require a healthcare provider to weigh the benefits of treatment against potential risks:
As mentioned, butenafine belongs to the benzylamine class. Patients should be cautious if they have a history of sensitivity to:
> Important: Your healthcare provider will evaluate your complete medical history and any known allergies before prescribing or recommending Butenafine. Always disclose if you have had a reaction to any "cream" or "ointment" in the past.
Butenafine is classified as Pregnancy Category B under the older FDA system. This means that animal reproduction studies (using high doses given orally) have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, butenafine should be used during pregnancy only if clearly needed and under the direction of a physician. Systemic absorption is very low, which generally makes it a safer choice than oral antifungals, but caution is still warranted, especially during the first trimester.
It is not known whether butenafine is excreted in human milk. However, given that less than 1.5% of a topical dose is absorbed into the mother's bloodstream, the amount that could potentially reach the breast milk is likely to be extremely small. To minimize risk, nursing mothers should not apply butenafine to the breast or nipple area to prevent the infant from accidentally ingesting the cream or coming into direct skin contact with it. Always consult your healthcare provider before using any medication while breastfeeding.
Butenafine is approved for use in adolescents aged 12 and older. The safety and effectiveness in children under 12 have not been established. In pediatric patients, the ratio of skin surface area to body mass is higher than in adults, which could theoretically lead to higher systemic absorption. Therefore, use in children should be strictly limited to the recommended duration and area of application.
Clinical studies of butenafine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
No dosage adjustment is required for patients with renal impairment. The kidneys are responsible for excreting the small amount of metabolites that enter the systemic circulation, but the volume is so low that even significantly reduced kidney function does not lead to toxic accumulation of the drug.
No dosage adjustment is required for patients with hepatic impairment. While the liver processes absorbed butenafine, the levels are not high enough to cause concern in patients with liver disease. However, patients with severe liver failure (Child-Pugh Class C) should always be monitored by their physician when using any new medication.
> Important: Special populations require individualized medical assessment to ensure that the chosen treatment is the safest possible option for their specific physiological state.
Butenafine hydrochloride is a benzylamine derivative with a mechanism of action similar to that of the allylamine class of antifungals. It acts as a potent inhibitor of the enzyme squalene epoxidase. This enzyme is a key catalyst in the fungal sterol biosynthesis pathway. By inhibiting this enzyme, butenafine prevents the conversion of squalene to lanosterol. This leads to two primary consequences:
Butenafine is primarily fungicidal against dermatophytes. The time to onset of action is relatively fast, with many patients reporting a reduction in itching and redness within the first few days of treatment. However, the fungal clearance (evidenced by negative cultures) takes longer, which is why the full 2-to-4-week course is necessary. The duration of effect is prolonged due to the drug's high affinity for the lipids in the stratum corneum, allowing it to remain active in the skin for days after the last application.
| Parameter | Value |
|---|---|
| Bioavailability | < 1.5% (Topical) |
| Protein Binding | > 95% (Systemic portion) |
| Half-life | 35 - 150 hours (Skin terminal half-life) |
| Tmax | 6 hours (after repeated application) |
| Metabolism | Hepatic (Hydroxylation) |
| Excretion | Primarily Renal (as metabolites) |
Butenafine is classified as a Benzylamine Antifungal. It is closely related to the allylamine class (which includes terbinafine and naftifine). These classes are collectively known as squalene epoxidase inhibitors. They are distinct from the azole class (like clotrimazole or ketoconazole), which inhibits a different enzyme (14-alpha-demethylase) later in the ergosterol synthesis pathway.
Common questions about Butenafine Hydrochloride 1%
Butenafine is a topical antifungal medication used to treat various superficial skin infections caused by fungi. Its primary indications include tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It is also effective in treating tinea versicolor, a condition that causes discolored patches on the skin. By killing the fungus and preventing its growth, butenafine helps relieve symptoms like itching, burning, and cracking. It is available both as a prescription and over-the-counter in a 1% cream formulation.
The most common side effects of butenafine are localized to the area where the cream is applied. Patients frequently report mild skin irritation, which can manifest as a temporary burning or stinging sensation immediately after application. Other common reactions include redness (erythema), itching, or slight peeling of the skin. These effects are usually mild and do not require the patient to stop using the medication. If you experience severe blistering, swelling, or a spreading rash, you should contact your healthcare provider immediately.
Yes, you can typically drink alcohol while using butenafine cream. Because butenafine is applied topically to the skin, very little of the medication enters your bloodstream. This means there is no significant interaction between the drug and alcohol in your system. This is a major advantage over some oral antifungal tablets, which can put stress on the liver and may require alcohol restriction. However, it is always wise to consume alcohol in moderation for general health and to follow any specific advice given by your doctor.
Butenafine is generally considered to have a low risk during pregnancy, but it should only be used if clearly needed. It was previously classified as FDA Pregnancy Category B, meaning animal studies showed no harm to the fetus, but human data is limited. Because it is applied topically and systemic absorption is minimal, it is often preferred over oral antifungal medications when a fungal infection must be treated during pregnancy. You should always consult your obstetrician or healthcare provider before starting any new medication while pregnant to ensure it is appropriate for your specific situation.
Many patients begin to feel relief from symptoms like itching and burning within the first 24 to 48 hours of using butenafine. However, the visible rash may take several days or even a week to show significant improvement. Even if the skin looks completely healed, it is vital to continue applying the cream for the full duration recommended (usually 1 to 4 weeks depending on the infection). Stopping the treatment too early can allow remaining fungal spores to regrow, leading to a quick return of the infection.
You can stop using butenafine suddenly without experiencing withdrawal symptoms, but doing so before the infection is fully cleared is not recommended. Fungal infections are notorious for recurring if the treatment is not finished. If you stop the medication as soon as the itching stops, the fungus may not be completely eradicated from the deeper layers of the skin. To ensure the infection is gone for good, always complete the full course of treatment as directed by your healthcare provider or the product packaging.
If you miss a dose of butenafine, apply it as soon as you remember. If it is almost time for your next scheduled application, it is better to skip the missed dose and simply continue with your regular routine. Do not apply a double amount of cream to make up for the missed application, as this will not make the medication work faster and could increase the risk of skin irritation. Consistency is key to treating fungal infections, so try to apply the cream at the same time each day.
No, butenafine does not cause weight gain. Weight gain is typically a side effect associated with systemic medications, such as oral steroids or certain antidepressants, that affect metabolism or appetite. Since butenafine is a topical antifungal with negligible systemic absorption, it does not have the capacity to influence your body weight. If you experience unexplained weight gain while using this medication, it is likely due to another factor, and you should discuss it with your doctor.
Butenafine cream can generally be used alongside most oral medications because it does not enter the bloodstream in significant amounts. However, you should be cautious about using other topical products (creams, lotions, or ointments) on the same area of skin at the same time. Mixing products can interfere with the absorption of the antifungal or cause increased skin irritation. If you need to use multiple topical treatments, it is best to apply them at different times of the day and consult your pharmacist for guidance.
Yes, butenafine is available as a generic medication. While it was originally sold only under the brand name Mentax, several manufacturers now produce generic versions of the 1% cream. Additionally, it is available over-the-counter (OTC) in many countries, often found under the brand name Lotrimin Ultra or as store-brand antifungal creams. Generic versions contain the same active ingredient and are required by the FDA to meet the same standards of safety and efficacy as the original brand-name product.
Other drugs with the same active ingredient (Butenafine)